News Powered By:
- a collaborative partner.
CenterWatch News Online Headlines : November 25, 2014 2:30 am : Centerwatch
BioMarin Pharmaceutical, based in San Rafael, Calif., will acquire Prosensa for $17.75 per share, for a total up-front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016, and Europe no later than Feb. 15, 2017, respectively.
CenterWatch News Online Headlines : November 24, 2014 8:58 am : Centerwatch
CytRx, a biopharmaceutical R&D company specializing in oncology, has received notice from the FDA that its clinical trials for aldoxorubicin have been placed on partial clinical hold. All currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols, but no new patients can be enrolled until the clinical hold is lifted.
CenterWatch News Online Headlines : November 24, 2014 8:53 am : Centerwatch
Eighty percent of surveyed pharma companies outsource some portion of their government reimbursement budgets, including third-party audits that can help companies remain compliant to changing industry guidelines, according to Cutting Edge Information, a Research Triangle Park, N.C.-based pharmaceutical business intelligence provider.
CenterWatch News Online Headlines : November 24, 2014 8:50 am : Centerwatch
The Cell Therapy Catapult, focused on the development of the U.K. cell therapy industry, has collaborated with the U.K. Regenerative Medicine Platform, the Knowledge Transfer Network and the Association of Medical Research Charities to develop a database of U.K. cell therapy research funding.
CenterWatch News Online Headlines : November 24, 2014 8:49 am : Centerwatch
The Securities and Exchange Commission has suspended trading in four companies that claim to be developing products or services in response to the Ebola outbreak, citing a lack of publicly available information about the companies’ operations.